Anavar (Oxandralone) Thread, articles, research

[SHINE]

Oxandrolone is an orally active derivative of dihydrotestosterone, due to its 17methylation. It also differs from DHT by the substitution of its 2-carbon molecule with oxygen.This is the only commercial steroid to carry this group, and further, the only to have a modification to the base carbon structure of the Sterannucleus.The 2-oxo group increases resistance of the 3-keto group to metabolism considerably, making oxandrolone a potent anabolic.
A comprehensive collection of clinical studies on the use and safety of Anavar.

Now taken from Watson pharmaceuticals this is the Real half-life of Oxandralone!
single dose pharmacokinetic study of Oxandrolone in elderly subjects, the mean elimination half-life was 13.3 hours. In a previous single dose pharmacokinetic study in younger volunteers, the mean elimination half-life was 10.4 hour


may decrease levels of thyroxine-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4 as most steroids do. Free thyroid hormone levels remain unchanged. In addition, a decrease in PBI and radioactive iodine uptake may occur.


Commenting again on the above chemistry of Containing an oxygen rather than a carbon atom at the 2-posistion within the Phenanthrene nucleus It lacks a 4-ene function in the A-ring.
Anabolic activity is 6.0times greater than its androgenic activity and has been found t be 6.3 times greater than methyl test in anabolic activity.

do to the high anabolic to androgenic activity it is less likely to cause adverse cosmetic consequences in women than test analogs. Women will see water retention do to the fact it is still a mild androgen, edema (fluid retention), retention of serum electrolytes (potassium, sodium chloride, phosphate and calcium). Bio Chemical Individuality, these effects are worse in some than others.


Given to malnourished patients with alcoholic hepatitis it has been shown safe even up to doses of 80mg/day.
Below study shows this, this study showing 60mg ed.

Ox 17-methyl-17hydroxy-2-oxa-5-androstan-3-one) preparation of ox is described in iner alia, in U.S. Pat. No. 3,128,283,

http://patents.justi...3/04376733.html
http://www.docstoc.c...-Patent-7297801


Two known and accepted versions of oxandranlone, Most of your UG lab versions is questionable. Ox is not an easy formula to get down, however reports of those using the UG oxandrolone are giving alot better feed back than what was out a few years ago. If you can find Pharmaceutical oxandralone I would go with it any day over the UG/China based stuff

References
1. Rose W. (1992), Journal of Intravenous Nursing 15(1): 18-23
2. Donahoe et al. (1990), Clinics in Chest Medicine 11(3): 487-504.
3. Fox et al. (1962), J. Clin. Endocrinol. Metab. 22: 921-924.
4. Karim et al. (1973), Clin. Pharmacol. Therap. 14: 862-869.
5. Masse et al. (1989), Biomedical and Environmental Mass Spectrometry18:429-438.
6. Mendenhall et al. (1993), Hematology 17(4): 564-576.
7. Bonkovsky et al. (1991), The American Journal of Gastroenterology 86(9):1209-1218.




.oxandrolone virtualy non-toxic?
Anavar actually improves liver function in alcoholic hepatitis patients and even at 60mg doses!
Thing is OX is unique in the fact it is mainly processed in the kidneys and undergoes little hepatic metabolism, being excreted rather than processed through the liver, show in the below articles.
Bonkovsky HL, Fiellin DA, Smith GS, Slaker DP, Simon D, Galambos JT

Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.

The present studies were designed to provide careful measures of effects of oxandrolone, an anabolic steroid, intravenous nutritional supplementation, and the combination of these two treatments on liver functions, metabolic balances, nitrogen metabolism, and nutritional status in patients with moderate to severe alcoholic hepatitis. Of 43 patients originally recruited, 39 (19 men, 20 women) with typical clinical and laboratory features of alcoholic hepatitis (11 Child's-Pugh class B; 28 class C) were admitted to a metabolic unit and completed a 35-day three-phase protocol. Phase I was a 10-day baseline period of observation, during which routine and special quantitative tests of liver function (galactose and antipyrine metabolism), a 7-day elemental balance study, and a 15N, 13C-leucine metabolism study were done. Phase II was a 21-day treatment period during which patients were randomly assigned to receive one of four regimens: 1) standard therapy, consisting of abstinence, a balanced, nutritionally adequate diet, and multivitamins; 2) oxandrolone (20 mg orally four times a day) plus standard therapy; 3) nutritional supplementation, consisting of 2 L daily of 3.5% crystalline amino acids (in 5% dextrose), given by peripheral vein; or 4) a combination of oxandrolone and nutritional supplementation, along with standard therapy. Metabolic balances were repeated during phase II. Phase III was 2 or 3 days post-treatment, during which special studies of liver functions and volumes and leucine metabolism were repeated. All patients who completed phase I of study and were randomly allocated to one of the four treatment groups completed the subsequent two phases. Overall, with time, patients showed highly significant improvements in most clinical and laboratory features. For most standard laboratory tests (e.g., serum albumin, transferrin, prothrombin time) improvements were more marked in patients treated with nutritional supplementation and/or oxandrolone than in those given standard therapy alone. Liver volumes fell in all treatment groups, with greater improvement in those treated with nutritional supplementation. Improvements in galactose and antipyrine metabolism rates were significant only in those treated with nutritional supplementation or oxandrolone. Effects of treatments on metabolic balances, nitrogen metabolism, and measures of nutrition are described in this issue in a companion paper. We conclude that the addition of nutritional supplementation and oxandrolone to standard therapy of moderately severe or severe alcoholic hepatitis is well tolerated, and leads to more rapid improvement in the laboratory parameters measured.

 

[SHINE]

Oxandrolone being a decent cortisol blocker,

In this article

Oxandrolone blocks glucocorticoid signaling in an androgen receptor-dependent manner.

Zhao J, Bauman WA, Huang R, Caplan AJ, Cardozo C.

Rehabilitation and Research Development Center of Excellence for the Medical Consequences of Spinal Cord Injury, VA Medical Center, Bronx, NY, USA.

The anabolic steroid oxandrolone is increasingly used to preserve or restore muscle mass in those with HIV infection or serious burns. These effects are mediated, in part, by the androgen receptor (AR). Anti-glucocorticoid effects have also been reported for some anabolic steroids, and the goal of our studies was to determine whether oxandrolone had a similar mechanism of action. Studies with in vitro translated glucocorticoid receptor (GR), however, showed no inhibition of cortisol binding by oxandrolone. Conversely, experiments in cell culture systems demonstrated significant antagonism of cortisol-induced transcriptional activation by oxandrolone in cells expressing both the AR and GR. Inhibition was not overcome by increased cortisol concentration, and no inhibition by oxandrolone was observed in cells expressing GR alone, confirming that non-competitive mechanisms were involved. AR-dependent repression of transcriptional activation by oxandrolone was also observed with the synthetic glucocorticoids dexamethasone and methylprednisolone. Furthermore, the AR antagonists 2-hydroxyflutamide and DDE also repressed GR transactivation in an AR-dependent manner. A mutant AR lacking a functional nuclear localization signal (AR(4RKM)) was active in oxandrolone-mediated repression of GR even though oxandrolone-bound AR(4RKM) failed to enter the nucleus and did not affect nuclear import of GR. These data indicate a novel action of oxandrolone to suppress glucocorticoid action via crosstalk between AR and GR.

http://www.sciencedirect.com/science/article/pii/S0039128X0400051

 

[SHINE]

Reversal of COPD-Associated Weight Loss Using the Anabolic Agent Oxandrolone

http://journal.publications.chestnet.org/article.aspx?articleid=1080843

Another noteworthy observation in this study was that oxandrolone was very well-tolerated by women, who comprised more than half the study sample. We believe this is the first study of anabolic steroids in patients with COPD associated weight loss in which women are significantly represented. Although treated with the maximum approved daily dose for adults, only 6 of 71 women (11.8%) had androgenic effects. This is important, as the prevalence of women with symptomatic COPD and associated weight loss is expected to rise as a result of the increased numbers of women smokers over the past few decades.


Although not presented herewith, proinflammatory cytokines and leptin levels were evaluated on the patients studied at one center. These were elevated at baseline and were observed to have decreased by the end of treatment, in association with increased body weight.34 These results underscore the systemic nature of COPD and associated weight loss, and the potential role for oxandrolone in the management of this problem. The results of an ongoing, randomized, placebo-controlled COPD trial are anticipated to provide more definitive information regarding the effects of oxandrolone in this population.